Espinoza Octavio's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed May 17, 2024
- Accession no.
- 0002001011-24-000053
- Filed
- May 17, 2024
- Trade date
- May 15-17, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $1.15M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Espinoza OctavioCIK 0001905248 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2024 | Common Stock | SSaleDisposed | −5,873 | $86.01F1 | −$505,136.73 | 23,882 | Direct | |
| May 16, 2024 | Common Stock | SSaleDisposed | −2,264 | $86.00F2 | −$194,704 | 21,618 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseAcquired | +206 | $57.22 | +$11,787.32 | 21,824 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseAcquired | +1,544 | $63.62 | +$98,229.28 | 23,368 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseAcquired | +145 | $68.74 | +$9,967.3 | 23,513 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseAcquired | +5,022 | $52.84 | +$265,362.48 | 28,535 | Direct | |
| May 17, 2024 | Common Stock | SSaleDisposed | −5,022 | $86.67F3 | −$435,256.74 | 23,513 | Direct | |
| May 17, 2024 | Common Stock | SSaleDisposed | −134 | $86.65 | −$11,611.1 | 23,379 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 17, 2024 | Common Stock | MOption exerciseDisposed | −206 | $0.00 | $0 | 7,516 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseDisposed | −1,544 | $0.00 | $0 | 18,456 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseDisposed | −145 | $0.00 | $0 | 0 | Direct | |
| May 17, 2024 | Common Stock | MOption exerciseDisposed | −5,022 | $0.00 | $0 | 16,179 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.1500. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0000 to $86.0350. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.0300 to $86.8200. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.